HFSA Guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - Pharmacological approaches

Journal of Cardiac Failure

Volumn 5, Issue 4, 1999, Pages 357-382

  Adams Jr , Kirkwood F ^a   Baughman, Kenneth L ^a   Dec, William G ^a   Elkayam, Uri ^a   Forker, Alan D ^a   Gheorghiade, Mihai ^a   Hermann, Denise ^a   Konstam, Marvin A ^a   Liu, Peter ^a   Massie, Barry M ^a   Patterson, J Herbert ^a   Silver, Marc A ^a   Stevenson, Lynne Warner ^a   Cohn, Jay N ^a   Francis, Gary S ^a   Greenberg, Barry ^a   Leier, Carl ^a   Lorell, Beverly H ^a   Packer, Milton ^a   Pitt, Bertram ^a   Sonnenblick, Edmund ^a   Strobeck, John ^a   Walsh, Richard ^a   Yusuf, Salim ^a   more..

^a Heart Failure Society of America   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CARVEDILOL; CLOPIDOGREL; CYCLOSPORIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LOSARTAN; METOPROLOL; NITRATE; OKT 3; PREDNISONE; SPIRONOLACTONE; TICLOPIDINE; UNINDEXED DRUG; WARFARIN; ANGIOTENSIN RECEPTOR; CARDIOVASCULAR AGENT;

ANTICOAGULANT THERAPY; ARTIFICIAL HEART PACEMAKER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; MYOCARDITIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOEMBOLISM; TREATMENT INDICATION; CLASSIFICATION; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; FEMALE; HEART LEFT VENTRICLE FUNCTION; MALE; SYSTOLE; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANTICOAGULANTS; CARDIOVASCULAR AGENTS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; RECEPTORS, ANGIOTENSIN; SYSTOLE; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0033253481     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. American Heart Association: 1998 Heart and Stroke Statistical Update. Dallas, TX, American Heart Association, 1997
2. Ho KKL, Pinsky JL, Kannel WB, Levy D: The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993;22(suppl):6A-13A
3. Eriksson H: Heart failure: a growing public health problem. J Intern Med 1995;237:135-41
4. Massie BM, Shah NB: Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997;133:703-12
5. Ghali JK, Cooper R, Ford E: Trends in hospitalization rates for heart failure in the United States, 1973-1986: evidence for increasing population prevalence. Arch Intern Med 1990;150:769-73
6. Graves EJ: National hospital discharge survey: annual summary, 1993. Vital and Health Statistics, Series 13: data from National Health Survey. Washington, DC, US Government Printing Office, 1995;121:1-63
7. Centers for Disease Control and Prevention: Cerebrovascular disease mortality and Medicare hospitalization - United States, 1980-1990. MMWR 1992;41:477-80
8. Adams KF, Zannad F: Clinical definition of advanced heart failure. Am Heart J 1998;135:S204-15
9. O'Connell JB, Bristow MR: Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994;13:S107-12
10. Packer M: How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol 1993; 71(suppl):3C-11
11. Cohn JN: Vasodilator therapy for heart failure: the influence of impedance on left ventricular performance. Circulation 1973;48:5-8
12. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN: The neurohormonal axis in congestive heart failure. Ann Intern Med 1984;101:370-7
13. Packer M: The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54
14. Pfeffer MA, Braunwald E: Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990;81:1161-72
15. Cohn JN: Structural basis for heart failure: ventricular remodeling and its pharmacologic inhibition. Circulation 1995;91:2504-7
16. Eichhorn EJ, Bristow MR: Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996;94:2285-96
17. Gheorghiade M, Bonow RO: Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 1998;97:282-9
18. Konstam MA, Dracup K, Baker D, Bottorff M, Brooks NH, Dacey RA, Dunbar SB, Jackson A, Jessup M, Johnson JC, Jones RH, Luchi RJ, Massie BM, Pitt B, Rose EA, Rubin LJ, Wright RF, Hadorn DC: Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. Rockville, MD, Agency for Health Care Policy and Research, US Dept. of Health and Human Services, 1994
19. ACC/AHA Task Force on Practice Guidelines: Guidelines for the evaluation and management of heart failure. Circulation 1995;92:2764-84
20. Task Force of the Working Group for Heart Failure of the European Society of Cardiology: The treatment of heart failure. Eur Heart J 1997;18:736-53
21. Packer M, Cohn JN on behalf of the Steering Committee and Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure: Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999;83(suppl):1A-38
22. Eichhorn EJ, Bristow MR: Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997;79:794-8
23. Sackner-Bernstein JD, Mancini DM: Rationale for treatment of patients with chronic heart failure with adrenergic blockade. JAMA 1995;274:1462-7
24. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I: Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1979;1: 374-6
25. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Biossel JP: Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998; 98:1184-91
26. Heidenreich PA, Lee TT, Massie BM: Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27-34
27. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55
28. CIBIS Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial of beta-blockade in heart failure. Lancet 1999;353: 9-13
29. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7
30. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:-1441-6
31. The International Steering Committee: Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). Am J Cardiol 1997;80(suppl):54J-8
32. CIBIS Investigators and Committees: A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90: 1765-73
33. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH: Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Circulation 1996;94:2793-9
34. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16
35. Australia/New Zealand Heart Failure Research Group: Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-80
36. The SOLVD Investigators: Effect of enalapril on mortality and the development on heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91
37. Krum H, Gu A, Wilshire-Clement M, Sackner-Bernstein J, Goldsmith R, Medina N, Yushak M, Miller M, Packer M: Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-1506
38. Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, LeJemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA for the US Carvedilol Heart Failure Study Group: Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. J Card Fail 1997; 3:173-9
39. Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A: Long-term beta-blockade in dilated cardiomyopathy: effects of short-term and long-term metoprolol followed by withdrawal and readministration of metoprolol. Circulation 1989;80:551-63
40. Morimoto S, Shimizu K, Yamada K, Hiramitsu S, Hishida H: Can beta-blocker therapy be withdrawn form patients with dilated cardiomyopathy. Am Heart J 1999; 137:456-9
41. Uretsky BF, Pina I, Quigg RJ, Brill JV, Maclnerney EJ, Mintzer R, Armstrong PW: Beyond drug therapy: nonpharmacologic care of the patient with advanced heart failure. Am Heart J 1998;135(suppl):S264-84
42. The Digitals Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33
43. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK: Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993;22:955-62
44. Packer M, Gheorghiade M, Young JB, Constantini PJ, Adams KF, Cody RJ, Smith LK, Van Voorhees L, Gourley LA, Jolly MK: Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin converting enzyme inhibitors. N Engl J Med 1993;329:1-7
45. Young JB, Gheorghiade M, Uretsky BF, Patterson JH, Adams KF: Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials. J Am Coll Cardiol 1998;32:686-92
46. Adams KF, Gheorghiade M, Uretsky BF, Patterson JH, Schwartz TA, Young JB: Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol (abstract) 1999;33:185A
47. Gheorghiade M, Pitt B: Digitalis investigation group (DIG) trial: a stimulus for further research. Am Heart J 1997;134:3-12
48. Glaxo Wellcome, Inc: Lanoxin: Package Insert. Research Triangle Park, NC, Glaxo Wellcome, Inc, 1997
49. Gheorghiade M, Ferguson D: Digoxin: a neurohormonal modulator in heart failure? Circulation 1991;84:2181-6
50. Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG: Sympathoinhibitory responses to digitalis glycosides in heart failure patients: direct evidence from sympathetic neural recordings. Circulation 1989;80: 65-77
51. Krum H, Bigger JT, Goldsmith RL, Packer M: Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. J Am Coll Cardiol 1995; 25:289-94
52. Adams KF, Gheorghiade M, Uretsky BF, Young JB, Ahmed S, Tomasko L, Packer M: Patients with mild heart failure worsen during withdrawal from digoxin therapy. J Am Coll Cardiol 1997;30:42-8
53. The Captopril Multicenter Research Group: Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988;259: 539-44
54. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R: A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989;320:677-83
55. Gheorghiade M, Hall VB, Jacobsen G, Alam M, Rosman H, Goldstein S: Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. Circulation 1995;92:1801-17
56. Newton GE, Tong JH, Schofield AM, Baines AD, Floras JS, Parker JD: Digoxin reduces cardiac sympathetic activity in severe congestive heart failure. J Am Coll Cardiol 1996;28:155-61
57. Slatton ML, Irani WN, Hall SA, Marcoux LG, Page RL, Grayburn PA, Eichhorn EJ: Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm? J Am Coll Cardiol 1997;29: 1206-13
58. Zarowitz BJ, Gheorghiade M: Optimal heart rate control for patients with chronic atrial fibrillation: are pharmacologic choices truly changing? Am Heart J 1992;123: 1401-3
59. Sbarouni E, Bradshaw A, Andreotti F, Tuddenham E, Oakley CM, Cleland JG: Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994;127:607-12
60. Jafri SM, Ozawa T, Mammen E, Levine TB, Johnson C, Goldstein S: Platelet function, thrombin and fibrinolytic activation in patients with heart failure. Eur Heart J 1993; 14:205-12
61. Yamamoto K, Ikeda U, Furuhashi K, Irokawa M, Nakayama TM, Shimada K: The coagulation system is activated in idiopathic cardiomyopathy. J Am Coll Cardiol 1995;25:1634-40
62. Fuster V, Gersh B, Giuliani E, Tajik AJ, Brandenburg RO, Frye RL: The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981;47:525-30
63. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn J for the V-HeFT Cooperative Studies Group: Incidence of thromboembolic events in congestive heart failure. Circulation 1993;87(S):VI-94-101
64. Ciaccherie M, Castelli Q, Cecchi F, Nannini M, Santoro G, Troiani V, Zuppiroli A, Dolara A: Lack of correlation between intracavitary thrombosis detected by cross-sectional echocardiography and systemic emboli in patients with dilated cardiomyopathy. Br Heart J 1989;62:26-9
65. Kyrle P, Korninger C, Gossinger H, et al: Prevention of arterial pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy. Thromb Haemost 1985;54:521-3
66. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE: Antithrombotic therapy in atrial fibrillation. Chest 1998;114(suppl):579S-89
67. Natterson PD, Stevenson WG, Saxon LA, Middlekauff HR, Stevenson LW: Risk of arterial embolization in 224 patients awaiting cardiac transplantation. Am Heart J 1995;129:564-70
68. Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, Lamas GA, Moye LA, Goldhaber SZ, Pfeffer MA: Ventricular dysfunction predicts stroke following myocardial infarction. N Engl J Med 1997;336:251-7
69. Dries DL, Rosenberg Y, Waclawiw M, Domanski M: Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997;29: 1074-80
70. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA: Warfarin anticoagulation and survival: a cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol 1998;31:749-53
71. Smith P, Arnesen H, Holme I: The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-52
72. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG: Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 1985;313:1369-75
73. Collins R, Peto R, Baigent C, Sleight P: Aspirin, heparin and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336:847-60
74. ISIS-2 Collaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60
75. Antiplatelet Trialist's Collaboration: Collaborative overview of randomized trials of antiplatelet therapy-I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106
76. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA: Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998;31: 419-25
77. Nguyen KN, Aursnes I, Kjekshus J: Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997;79:115-9
78. Peterson JG, Lauer MS, Young JB, Sapp S, Califf RM, Topol EJ: Evidence for an adverse interaction between ACE inhibitors and aspirin following myocardial infarction: the GUSTO-1 Trial. J Am Coll Cardiol (Abstract) 1998;31:96A
79. Leor J, Reicher-Reiss H, Goldbour U, Boyko V, Gottlieb S, Battler A, Behar S: Aspirin and mortality in patients treated with angiotensin-converting enzyme. J Am Coll Cardiol 1999;33:1920-5
80. Nawarskas JJ, Spinier SA: Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure? Pharmacotherapy 1998;18:1041-52
81. Hall D, Zeitler H, Rudolph W: Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992;20:1549-55
82. Oosterga M, Anthonio RL, de Kam PJ, Kingma JH, Crijns HJ, van Gilst WH: Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction. Am J Cardiol 1998;81:1178-81
83. Sharis PJ, Cannon CP, Loscalzo J: The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998;129: 394-405
84. CAPRIE Steering Committee: A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 1996;348:1329-39
85. Spaulding C, Charbonnier B, Cohen-Solal A, Juilliere Y, Kromer EP, Benhamda K, Cador R, Weber S: Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial Circulation 1998;98:757-65
86. Pitt B. Konstam MA: Overview of angiotensin II receptor antagonists. Am J Cardiol 1998;82(suppl):47S-9
87. Crozier J, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, Rucinska E for the Losartan Hemodynamic Study Group: Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995;91:691-7
88. Dickstein K, Chang P, Willenheimer R, Haunso S, Remes J, Hall C, Kjekshus J: Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe heart failure. J Am Coll Cardiol 1995;26:438-45
89. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI: Randomized trial of losartan versus captopril in patients over 65 with heart failure (ELITE). Lancet 1997; 349:747-51
90. Pitt B, Poole-Wilson P, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B: Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of the patients in the Losartan Heart Failure Survival Study (ELITE II). J Card Fail 1999;5:146-54
91. Pitt B, Poole-Wilson P: Presentation at the American Heart Association 72nd Scientific Session, Atlanta, GA, November 1999
92. Yusuf S, Maggioni AP, Held P, Rouleau JL: Effects of candesartan, enalapril, or their combinations on exercise capacity, ventricular function, clinical deterioration, and quality of life in heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD). (abstract) Circulation 1997;96:1-452
93. Granger CB, Ertl G, Kuch J, McMurray J, Rouleau JL, Swedberg K, Young JB, Yusuf S, Held P, Pfeffer MA on behalf of the SPICE Investigators: A randomized trial evaluating tolerance to candesartan cilexitil in patients with congestive heart failure and intolerance to angiotensin converting enzyme inhibitors. (Abstract) J Am Coll Cardiol 1999;33:189A
94. Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, Jondeau G, Olivari MT, Thomas S, LeJemtel TH: Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe heart failure. Circulation 1999;99:990-2
95. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG: Antiarrbythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-32
96. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, Huther ML, Richardson DW and the CAST Investigators: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324: 781-8
97. Waldo AL, Camm AJ, deRuyter H, Freidman PLF, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP for the SWORD Investigators: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348:7-12
98. Bloch-Thompsen PE for the DIAMOND-MI investigators presented at the 70th Scientific Sessions of the American Heart Association. Danish investigation of arrhythmia and mortality on dofetilide. (Abstract) Clin Cardiol 1998;21:52-4
99. Doval HC, Nul DR, Grencelli HO, Perrone SV, Bortman GR, Curiel R for the GESICA Investigators: Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-8
100. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D for the CHF-STAT Investigators: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;33:77-82
101. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P for the EMIAT Investigators: Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction. Lancet 1997;349:667-74
102. Cairns JA, Connolly SI, Roberts R, Gent M for the CAMIAT Investigators: Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations. Lancet 1997;349:675-82
103. Amiodarone Trials Meta-Analysis Investigators: Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6,500 patients in randomized trials. Lancet 1997;350:1417-24
104. Moss AJ, Hall WJ, Cannon DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M for the MADIT Investigators: Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-40
105. AVID Investigators: A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-83
106. Cappato R: Secondary prevention of sudden death: The Dutch Study, the Antiarrhythmics Versus Implantable Defibrillator Trial, the Cardiac Arrest Study Hamburg, and the Canadian Implantable Defibrillator Study. Am J Cardiol 1999;83(suppl):68D-73
107. Moss AJ, Cannon DS, Daubert JP, Hall WJ, Higgins SL, Klein H, Wilber D, Zareba W, Brown WU for the MADITT II Investigators: Multicenter Automatic Defibrillator Implantation Trial II (MADITT II): design and clinical protocol. Ann Noninv Electrocardiol 1999;4: 83-91
108. Klein H, Auricchio A, Reek S, Geller C: New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Am J Cardiol 1999;83(suppl):91D-7
109. Laragh JH: Hormones and the pathogenesis of congestive heart failure: vasopression, aldosterone, and angiotensin II: further evidence for a renal adrenal interaction from studies of hypertension and cirrhosis. Circulation 1962; 25:1015-22
110. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH: Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63:645-51
111. Wang W: Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994;24:571-5
112. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-65
113. Duprez DA, De Buyzere ML, Rietzschel ER, Taes Y, Clement DL, Morgan D, Cohn JN: Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998;19:1371-6
114. Okubo S, Niimura F, Nishimura H, Takemoto F, Fogo A, Matsusaka T, Ichikawa I: Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 1997;99:855-60
115. Struthers AD: Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996;2:47-54
116. The RALES Investigators: Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure. Am J Cardiol 1996;78:902-7
117. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17
118. Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ Jr., Olsen EG, Schoen FJ: Myocarditis: a histopathologic definition and classification. Am J Cardiovasc Pathol 1987;1:3-14
119. Dec GW, Palacios IF, Fallon JT, Aretz HT, Mills J, Lee DC, Johnson RA: Active myocarditis in the spectrum of acute dilated cardiomyopathies: clinical features, histologic correlates, and clinical outcome. N Eng J Med 1985;312:885-90
120. Vignola PA, Aonuma K, Swaye PS, Rozanski JJ, Blankstein RL, Benson J, Gosselin AJ, Lister JW: Lymphocytic myocarditis presenting as unexplained ventricular arrhythmias: diagnosis with endomyocardial biopsy and response to immunosuppression. J Am Coll Cardiol 1984; 4:812-9
121. Dec GW, Waldman H, Southem J, Fallon JT, Hutter AM, Palacios I: Viral myocarditis mimicking acute myocardial infarction. J Am Coll Cardiol 1992;20:85-9
122. Grogan M, Redfield MM, Bailey KR, Reeder GS, Gersh BJ, Edwards WD, Rodeheffer RJ: Long-term outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1995;26:8-14
123. O'Connell JB, Mason JW: Diagnosing and treating active myocarditis. West J Med 1989;150:431-5
124. Jones SR, Herskowitz A, Hutchins GM, Baughman KL: Effects of immunosuppressive therapy in biopsy-proved myocarditis and borderline myocarditis on left ventricular function. Am J Cardiol 1991;68:370-6
125. Parillo JE, Cunnion RE, Epstein SE, Parker MM, Suffredini AF, Brenner M, Schaer GL, Palmeri ST, Cannon RO 3d, Ailing D, Wittes JT, Ferrans VJ, Rodriguez ER, Fauci AS: A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Eng J Med 1989; 321:1061-8
126. Latham RD, Mulrow JP, Virmani R, Bobinowitz M, Moody JM: Recently diagnosed idiopathic dilated cardiomyopathy: incidence of myocarditis and efficacy of prednisone therapy. Am Heart J 1989;117:876-81
127. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE: A clinical trial of immunosuppressive therapy for myocarditis. N Eng J Med 1995;333:269-75
128. Drucker NA, Colan SD, Lewis AB, Beiser AS, Wessel DL: Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 1994;89:252-7
129. McNamara DM, Rosenblum WD, Janosko KM, Trost MK, Villaneuva FS, Demetris AJ, Murali S, Feldman AM: Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 1997;95: 2476-8
130. The Criteria Committee of the New York Heart Association: Nomenclature and criteria for the diagnosis of the heart and great vessels (8th edition). Boston, MA, Little Brown and Co, 1979 (modified to add class IIIa and IIIb)